Eli Lilly’s Prevail strikes potential billion-dollar AAV capsids deal with Sangamo for neurological diseases

Eli Lil­ly’s Pre­vail Ther­a­peu­tics has ex­pand­ed again in­to neu­ro­log­i­cal tar­gets thanks to a po­ten­tial bil­lion-dol­lar deal with Sang­amo Ther­a­peu­tics. The pair will eval­u­ate some of Sang­amo’s ade­no-as­so­ci­at­ed virus (AAV) cap­sids with the po­ten­tial to li­cense the cap­sids for gene ther­a­pies.

The AAV cap­sids were gen­er­at­ed us­ing Sang­amo’s SIFTER plat­form but they’re still ear­ly-stage, ac­cord­ing to the com­pa­ny, show­ing “po­ten­tial” ef­fi­cient de­liv­ery of gene ther­a­pies to the cen­tral ner­vous sys­tem in pre­clin­i­cal an­i­mal mod­els.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN